maklogo
Market Research Report

Global Oligonucleotide Synthesis Services Market Insights, Size, and Forecast By Scale (Custom Synthesis, Large Scale Production, Standardized Synthesis), By End Use (Academic Institutions, Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations), By Application (Research, Therapeutics, Diagnostic, Drug Discovery), By Product Type (RNA Oligonucleotides, DNA Oligonucleotides, PCR Products, MicroRNA), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Key Companies, Competitive Analysis, Trends, and Projections for 2026-2035

Report ID:50291
Published Date:Jan 2026
No. of Pages:220
Base Year for Estimate:2025
Format:
Customize Report

Key Market Insights

Global Oligonucleotide Synthesis Services Market is projected to grow from USD 4.1 Billion in 2025 to USD 12.8 Billion by 2035, reflecting a compound annual growth rate of 14.2% from 2026 through 2035. This robust growth underscores the increasing demand for synthetic oligonucleotides across various scientific and clinical applications. Oligonucleotide synthesis services encompass the custom manufacturing of short, synthetic DNA or RNA molecules for research, diagnostic, and therapeutic purposes. Key market drivers include the burgeoning advancements in genomics and molecular biology, the rising adoption of next generation sequencing NGS technologies, and the growing pipeline of oligonucleotide based therapeutics. Furthermore, the increasing prevalence of chronic diseases and genetic disorders necessitates innovative diagnostic and treatment approaches, fueling the demand for personalized medicine and gene therapies that heavily rely on synthetic oligonucleotides. The research segment currently holds the largest market share, indicating the foundational role of these services in academic and industrial scientific discovery.

Global Oligonucleotide Synthesis Services Market Value (USD Billion) Analysis, 2025-2035

maklogo
14.2%
CAGR from
2025 - 2035
Source:
www.makdatainsights.com

Important market trends shaping the landscape include the development of highly efficient and cost effective synthesis platforms, the integration of automation and artificial intelligence to optimize synthesis processes, and the expansion into complex modified oligonucleotides for specialized applications. Conversely, market restraints include the high capital investment required for advanced synthesis technologies, the stringent regulatory landscape for therapeutic oligonucleotides, and the technical complexities associated with synthesizing longer and more complex sequences. Nevertheless, significant market opportunities exist in the expansion into emerging therapeutic areas such as gene editing with CRISPR Cas technology, the development of novel drug delivery systems for oligonucleotide therapeutics, and the increasing demand for high throughput screening applications. The shift towards personalized medicine and the growing need for custom designed oligonucleotides for diagnostics further present substantial growth avenues for service providers.

North America leads the global market, primarily due to the strong presence of major biotechnology and pharmaceutical companies, robust research and development infrastructure, and significant government and private funding for life sciences research. The region benefits from early adoption of advanced genomic technologies and a high concentration of skilled professionals. Asia Pacific is poised to be the fastest growing region, driven by expanding research activities, increasing healthcare expenditure, and the rising number of contract research organizations CROs and contract development and manufacturing organizations CDMOs. Key players such as Marathon Pharmaceuticals, Bioneer, IDT, Thermo Fisher Scientific, BioRad Laboratories, Synthego, Eurofins Genomics, GenScript, Integrated DNA Technologies, and LGC Group are focusing on strategic collaborations, acquisitions, and new product launches to enhance their service offerings and expand their global footprint. These companies are investing in R&D to develop innovative synthesis chemistries and purification methods, catering to the evolving needs of their diverse client base across applications, product types, end uses, and scales. Their strategies often involve offering comprehensive solutions, from custom synthesis to quality control and technical support, to secure a competitive advantage.

Quick Stats

  • Market Size (2025):

    USD 4.1 Billion

  • Projected Market Size (2035):

    USD 12.8 Billion

  • Leading Segment:

    Research (45.2% Share)

  • Dominant Region (2025):

    North America (41.2% Share)

  • CAGR (2026-2035):

    14.2%

Global Oligonucleotide Synthesis Services Market Emerging Trends and Insights

AI Driven Oligonucleotide Design and Optimization

AI driven oligonucleotide design and optimization is revolutionizing global oligonucleotide synthesis services. This trend leverages artificial intelligence to predict optimal sequences with unprecedented accuracy. AI algorithms analyze vast datasets of existing oligonucleotides, their binding characteristics, and cellular uptake, identifying patterns human researchers might miss. This allows for the de novo design of novel oligonucleotides with enhanced specificity, stability, and reduced off target effects for various applications like therapeutics and diagnostics. Furthermore, AI optimizes existing sequences by suggesting modifications that improve efficacy or lower immunogenicity. This iterative design process, guided by AI, significantly reduces experimental trial and error, accelerating discovery and development timelines. The result is the creation of more effective and safer oligonucleotide based drugs and research tools, driving innovation across the biotechnology and pharmaceutical industries.

Scalable Synthesis for Next Gen Therapies

The oligonucleotide synthesis services market is witnessing a major trend toward scalable synthesis for next generation therapies. This reflects the critical need for manufacturing capabilities that can support the rapid development and commercialization of advanced therapeutic modalities like gene therapies, CRISPR based editors, and RNA interference drugs.

As these innovative therapies transition from preclinical research to clinical trials and eventual market approval, there is an exponential increase in demand for high quality, sequence specific oligonucleotides. The industry is moving beyond small scale, academic oriented synthesis to robust, large scale manufacturing platforms capable of producing diverse oligonucleotides in significant quantities under stringent quality control. This includes developing automated, high throughput synthesis systems and optimizing chemical processes to achieve greater yields, purity, and reduced turnaround times, all essential for accelerating the availability of these life changing treatments to patients globally.

Automated High Throughput Oligo Manufacturing

Automated high throughput oligo manufacturing is a transformative trend within oligonucleotide synthesis services. This advancement leverages robotics and sophisticated liquid handling systems to dramatically increase production capacity and speed. Instead of manual, labor intensive processes, machines now precisely synthesize multiple oligonucleotides simultaneously, reducing human error and improving reproducibility. This automation allows service providers to fulfill a larger number of orders, especially for projects requiring extensive oligo libraries or combinatorial synthesis. The enhanced efficiency translates to quicker turnaround times for researchers and pharmaceutical companies, accelerating drug discovery, diagnostic development, and gene editing applications. It signifies a move towards industrial scale production, making custom oligos more accessible and affordable for a wider range of high demand applications globally.

What are the Key Drivers Shaping the Global Oligonucleotide Synthesis Services Market

Rising Demand for Oligonucleotide Therapeutics and Diagnostics

The growing recognition of oligonucleotide based therapeutics and diagnostics is a primary driver in the global oligonucleotide synthesis services market. Oligonucleotides are central to developing novel treatments for a wide array of diseases including cancer, genetic disorders, and infectious diseases. Their ability to precisely target specific genes or RNA sequences makes them highly attractive for personalized medicine and gene editing applications. The increasing number of oligonucleotide drug candidates entering preclinical and clinical development phases necessitates a greater demand for high quality, custom synthesized oligonucleotides. Furthermore, their utility in diagnostic tools for early disease detection and biomarker identification further fuels this demand. This expanding pipeline across both therapeutic and diagnostic sectors is significantly boosting the need for specialized oligonucleotide synthesis services to support research, development, and commercialization efforts.

Advancements in Oligonucleotide Synthesis Technologies

Advancements in oligonucleotide synthesis technologies are a key driver in the global oligonucleotide synthesis services market. Innovations in solid phase and enzymatic synthesis methods have dramatically improved efficiency purity and yield of synthesized oligonucleotides. These technological leaps enable the production of longer more complex sequences with greater accuracy and at lower costs. Such improvements are critical for applications in gene therapy CRISPR gene editing drug discovery diagnostics and nucleic acid based therapeutics. The demand for highly pure and custom oligonucleotides across research and clinical sectors directly fuels the need for sophisticated synthesis services. Enhanced automation and high throughput capabilities further accelerate discovery and development processes making advanced synthesis services indispensable for the expanding biotechnology and pharmaceutical industries.

Increasing R&D Investments in Genomics and Personalized Medicine

Genomics and personalized medicine are experiencing a surge in research and development funding. This increased investment directly fuels the demand for oligonucleotide synthesis services. Researchers in these fields require custom designed DNA and RNA sequences for various applications, including gene editing with CRISPR, developing new diagnostic tools, and creating targeted therapeutics. Oligonucleotides are fundamental building blocks for these advanced genomic technologies. As more resources are dedicated to understanding disease at a molecular level and tailoring treatments to individual patients, the need for high quality, custom oligonucleotides for experiments, drug discovery, and clinical trials expands significantly. This ongoing innovation and financial commitment in genomics inherently drives the growth of the oligonucleotide synthesis services market.

Global Oligonucleotide Synthesis Services Market Restraints

High Cost of Oligonucleotide Synthesis and Purification Limiting Wider Adoption

The significant expense associated with synthesizing and purifying oligonucleotides restricts their broader utilization across various applications. Each custom oligonucleotide requires specialized chemical reactions and purification steps, driving up production costs per unit. This high price point particularly impacts academic researchers and smaller biotechnology companies with limited budgets, hindering their ability to conduct extensive studies or develop affordable diagnostic and therapeutic solutions. Consequently, the financial burden deters widespread experimentation and the commercialization of oligonucleotide based products, creating a barrier to market expansion. Reducing these costs through technological advancements or economies of scale is crucial for unlocking the full potential of oligonucleotide applications.

Regulatory Hurdles and Stringent Quality Control Requirements Impeding Market Entry

Entering the global oligonucleotide synthesis services market is significantly hampered by strict regulatory scrutiny and demanding quality control standards. Companies face extensive validation requirements for their manufacturing processes, raw materials, and final products to ensure purity, efficacy, and safety. These requirements often involve complex documentation, multiple rounds of testing, and adherence to various international guidelines, such as Good Manufacturing Practices (GMP). Navigating this intricate web of regulations is time consuming and capital intensive, requiring substantial investments in specialized equipment, facilities, and personnel expertise. For new entrants, particularly smaller companies, the financial burden and lengthy approval timelines associated with meeting these stringent quality and regulatory thresholds create formidable barriers, making market penetration challenging.

Global Oligonucleotide Synthesis Services Market Opportunities

Meeting the Critical Demand for Clinical-Grade Oligonucleotides in Gene and Cell Therapy Commercialization

The commercialization surge in gene and cell therapies is generating an unprecedented and critical demand for clinical grade oligonucleotides. As these innovative treatments advance from research to patient application, there is an urgent need for synthesis services capable of delivering ultra pure, highly consistent, and regulatory compliant oligo products at scale. Existing production capacities often struggle to meet the stringent quality standards and bulk quantities required for Good Manufacturing Practice GMP compliant materials.

This represents a significant opportunity for oligonucleotide synthesis providers. Companies that can invest in robust manufacturing processes, advanced purification technologies, and comprehensive quality control systems will be uniquely positioned to support the burgeoning gene and cell therapy market. Furthermore, the rapid expansion of biotechnology and pharmaceutical development in regions like Asia Pacific intensifies this demand, driving the need for localized and globally accessible high quality synthesis solutions. Meeting this critical requirement is essential for enabling the widespread availability of transformative gene and cell therapies.

Driving Innovation in Customized Oligonucleotide Synthesis for Personalized Medicine and Advanced Diagnostics

The opportunity lies in pioneering novel approaches to customized oligonucleotide synthesis, a cornerstone for the accelerating growth of personalized medicine and advanced diagnostics. As healthcare transitions towards highly individualized treatments and precise disease detection, there is immense demand for bespoke, high quality oligo sequences. This involves developing innovative synthesis chemistries, optimizing production for complex modifications, and enhancing purification techniques to meet stringent regulatory requirements.

Driving innovation means delivering faster turnaround times, greater synthesis accuracy, and scalable solutions for diverse research and clinical applications. These encompass enabling next generation sequencing, gene editing technologies like CRISPR, mRNA based therapies, and sophisticated molecular diagnostics for early disease detection and companion diagnostics. The market rewards providers who can consistently deliver superior, tailored oligos, thereby accelerating scientific discovery and clinical translation globally. This directly empowers the future of precision healthcare, transforming patient outcomes through molecular specificity and targeted interventions.

Global Oligonucleotide Synthesis Services Market Segmentation Analysis

Key Market Segments

By Application

  • •Research
  • •Therapeutics
  • •Diagnostic
  • •Drug Discovery

By Product Type

  • •RNA Oligonucleotides
  • •DNA Oligonucleotides
  • •PCR Products
  • •MicroRNA

By End Use

  • •Academic Institutions
  • •Pharmaceutical Companies
  • •Biotechnology Companies
  • •Contract Research Organizations

By Scale

  • •Custom Synthesis
  • •Large Scale Production
  • •Standardized Synthesis

Segment Share By Application

Share, By Application, 2025 (%)

  • Research
  • Therapeutics
  • Drug Discovery
  • Diagnostic
maklogo
$4.1BGlobal Market Size, 2025
Source:
www.makdatainsights.com

Why is Research dominating the Global Oligonucleotide Synthesis Services Market?

The Research application segment holds the largest share, driven by increasing funding for life science research and the expanding use of oligonucleotides in genomics, proteomics, and molecular biology studies. Academic institutions and biotechnology companies heavily rely on synthesized oligonucleotides for gene editing, sequencing, and functional gene analysis. The continuous demand for novel therapeutic targets and diagnostic markers in early stage research also fuels this segment's growth, necessitating a broad range of custom and standardized oligonucleotide products.

How are end user dynamics shaping demand for specific product types in this market?

Pharmaceutical and biotechnology companies represent significant end users, driving demand particularly for DNA oligonucleotides and RNA oligonucleotides. These organizations require high purity and custom synthesis services for drug discovery, development of novel therapeutics, and advanced diagnostic applications. The need for precise genetic tools in preclinical trials and early drug development phases, often involving large scale production for consistency, underscores the critical role these end users play in dictating the volume and technical specifications of synthesized oligonucleotides.

What is the impact of synthesis scale on market offerings across various applications?

The market’s segmentation by scale into custom synthesis, large scale production, and standardized synthesis directly addresses the diverse needs across applications. Custom synthesis is pivotal for intricate research and early stage drug discovery, where unique sequence designs are frequently required. As projects advance into therapeutic development or diagnostic kit production, the demand shifts towards large scale production to ensure consistency and cost efficiency. Standardized synthesis serves routine applications, offering readily available and cost effective solutions.

Global Oligonucleotide Synthesis Services Market Regulatory and Policy Environment Analysis

The global oligonucleotide synthesis services market operates within a dynamic regulatory framework primarily shaped by end application. Therapeutic grade oligonucleotides demand rigorous Good Manufacturing Practice GMP compliance across all stages from raw material sourcing to final product synthesis and purification. Adherence to guidelines from authorities such as the FDA EMA and NMPA is critical ensuring product purity identity and safety for clinical use. Stringent quality management systems and comprehensive documentation are paramount for traceability and audit readiness. For research use only oligonucleotides regulations are less stringent yet still emphasize quality control and consistency. Ethical considerations particularly concerning gene editing applications influence policy development and responsible innovation. Furthermore import export controls and intellectual property rights add layers of complexity impacting global market access and competitive strategies. Continuous adaptation to evolving international standards is essential for service providers.

Which Emerging Technologies Are Driving New Trends in the Market?

The global oligonucleotide synthesis services market thrives on continuous innovation. Enzymatic synthesis, a significant emerging technology, is transforming traditional phosphoramidite chemistry, offering greener, more scalable production with enhanced purity. Advancements in automation and microfluidics are powering high throughput synthesis capabilities, crucial for rapid library generation in drug discovery and diagnostics. The market benefits from improved techniques for synthesizing longer, more complex oligonucleotides incorporating diverse modifications, vital for CRISPR guide RNAs, aptamers, and mRNA therapeutics. Innovations in quality control and purification ensure delivery of highly pure products. Artificial intelligence and machine learning are increasingly employed for optimizing oligo design and predicting synthesis efficiency, further accelerating service delivery and expanding applications across genomics, gene therapy, and synthetic biology. These technological leaps are driving market expansion.

Global Oligonucleotide Synthesis Services Market Regional Analysis

Global Oligonucleotide Synthesis Services Market

Trends, by Region

Largest Market
Fastest Growing Market
maklogo
41.2%

North America Market
Revenue Share, 2025

Source:
www.makdatainsights.com

Dominant Region

North America · 41.2% share

North America stands as the dominant region in the Global Oligonucleotide Synthesis Services Market, commanding an impressive 41.2% market share. This leadership is largely attributed to a robust biotechnology and pharmaceutical industry, significant research and development investments, and the widespread presence of leading contract research organizations and contract manufacturing organizations. The region benefits from a well-established scientific infrastructure and a highly skilled workforce, fostering innovation and the rapid adoption of advanced synthesis technologies. High funding for life sciences research and strong intellectual property protection further solidify North America's premier position. This concentration of expertise and resources drives continuous growth and technological advancements within the oligonucleotide synthesis services landscape.

Fastest Growing Region

Asia Pacific · 16.2% CAGR

Asia Pacific is poised to be the fastest growing region in the global oligonucleotide synthesis services market, demonstrating a robust Compound Annual Growth Rate CAGR of 16.2% from 2026 to 2035. This accelerated growth is primarily fueled by increasing research and development activities in genomics and biotechnology across countries like China, India, and Japan. The region benefits from a growing patient pool for genetic disorders and cancer, driving demand for personalized medicine and diagnostics that rely heavily on synthetic oligonucleotides. Furthermore, government initiatives supporting life science research, combined with rising healthcare expenditure and the establishment of new research facilities, are creating a fertile ground for market expansion. The expanding presence of contract research organizations and a skilled scientific workforce further contribute to this rapid upward trajectory.

Impact of Geopolitical and Macroeconomic Factors

Geopolitical tensions influence supply chains for key reagents, impacting lead times and service costs. Trade disputes or restrictions on chemical exports from specific regions could disrupt manufacturers' access to essential raw materials. Furthermore, intellectual property rights and patent enforcement in various countries significantly affect market entry and competition among oligonucleotide synthesis providers. Political stability and regulatory environments regarding genetic technologies also shape the market's growth trajectory, as stringent oversight can slow innovation and adoption.

Macroeconomic conditions, particularly inflation and interest rates, directly affect investment in research and development within pharmaceutical and biotechnology companies, the primary users of these services. A robust global economy encourages greater spending on drug discovery and personalized medicine, boosting demand for oligonucleotide synthesis. Conversely, economic downturns or recessions may lead to budget cuts, reducing outsourcing to synthesis service providers. Currency fluctuations also play a role, impacting the cost competitiveness of international providers and the affordability of services for clients in different regions.

Recent Developments

  • March 2025

    Thermo Fisher Scientific announced a strategic initiative to expand its oligonucleotide synthesis capacity in North America. This expansion aims to meet the growing demand for custom oligonucleotides used in therapeutic development and diagnostics, with a focus on high-throughput and GMP-grade production.

  • June 2025

    Integrated DNA Technologies (IDT) launched a new line of modified oligonucleotides specifically designed for CRISPR gene editing applications. These new products offer enhanced stability and delivery efficiency for guide RNAs, enabling more precise and effective genomic manipulations.

  • August 2024

    Eurofins Genomics completed the acquisition of a specialized oligonucleotide synthesis company based in Europe. This acquisition strengthens Eurofins' regional market presence and expands its portfolio of advanced synthesis services, particularly for challenging oligonucleotide designs.

  • November 2024

    GenScript announced a partnership with a leading biopharmaceutical company to provide large-scale, GMP-compliant oligonucleotide synthesis for a novel RNA therapeutic program. This collaboration highlights GenScript's capabilities in supporting advanced drug development with high-quality and scalable oligonucleotide manufacturing.

Key Players Analysis

Marathon Pharmaceuticals and Bioneer leverage proprietary synthesis platforms. IDT and Thermo Fisher Scientific dominate through advanced reagent manufacturing and comprehensive service portfolios, including high throughput synthesis. BioRad Laboratories and Synthego focus on innovative nucleic acid technologies. Eurofins Genomics and GenScript expand their global reach and specialized services. Integrated DNA Technologies and LGC Group utilize strong existing infrastructure and strategic acquisitions, driving market growth through expanding therapeutic applications and research demands for synthetic oligonucleotides.

List of Key Companies:

  1. Marathon Pharmaceuticals
  2. Bioneer
  3. IDT
  4. Thermo Fisher Scientific
  5. BioRad Laboratories
  6. Synthego
  7. Eurofins Genomics
  8. GenScript
  9. Integrated DNA Technologies
  10. LGC Group
  11. SigmaAldrich
  12. Pioneer Natural Resources
  13. Azenta Life Sciences

Report Scope and Segmentation

Report ComponentDescription
Market Size (2025)USD 4.1 Billion
Forecast Value (2035)USD 12.8 Billion
CAGR (2026-2035)14.2%
Base Year2025
Historical Period2020-2025
Forecast Period2026-2035
Segments Covered
  • By Application:
    • •Research
    • •Therapeutics
    • •Diagnostic
    • •Drug Discovery
  • By Product Type:
    • •RNA Oligonucleotides
    • •DNA Oligonucleotides
    • •PCR Products
    • •MicroRNA
  • By End Use:
    • •Academic Institutions
    • •Pharmaceutical Companies
    • •Biotechnology Companies
    • •Contract Research Organizations
  • By Scale:
    • •Custom Synthesis
    • •Large Scale Production
    • •Standardized Synthesis
Regional Analysis
  • North America
  • • United States
  • • Canada
  • Europe
  • • Germany
  • • France
  • • United Kingdom
  • • Spain
  • • Italy
  • • Russia
  • • Rest of Europe
  • Asia-Pacific
  • • China
  • • India
  • • Japan
  • • South Korea
  • • New Zealand
  • • Singapore
  • • Vietnam
  • • Indonesia
  • • Rest of Asia-Pacific
  • Latin America
  • • Brazil
  • • Mexico
  • • Rest of Latin America
  • Middle East and Africa
  • • South Africa
  • • Saudi Arabia
  • • UAE
  • • Rest of Middle East and Africa

Table of Contents:

1. Introduction
1.1. Objectives of Research
1.2. Market Definition
1.3. Market Scope
1.4. Research Methodology
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Market Factor Analysis
4.1. Porter's Five Forces Model Analysis
4.1.1. Rivalry among Existing Competitors
4.1.2. Bargaining Power of Buyers
4.1.3. Bargaining Power of Suppliers
4.1.4. Threat of Substitute Products or Services
4.1.5. Threat of New Entrants
4.2. PESTEL Analysis
4.2.1. Political Factors
4.2.2. Economic & Social Factors
4.2.3. Technological Factors
4.2.4. Environmental Factors
4.2.5. Legal Factors
4.3. Supply and Value Chain Assessment
4.4. Regulatory and Policy Environment Review
4.5. Market Investment Attractiveness Index
4.6. Technological Innovation and Advancement Review
4.7. Impact of Geopolitical and Macroeconomic Factors
4.8. Trade Dynamics: Import-Export Assessment (Where Applicable)
5. Global Oligonucleotide Synthesis Services Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
5.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
5.1.1. Research
5.1.2. Therapeutics
5.1.3. Diagnostic
5.1.4. Drug Discovery
5.2. Market Analysis, Insights and Forecast, 2020-2035, By Product Type
5.2.1. RNA Oligonucleotides
5.2.2. DNA Oligonucleotides
5.2.3. PCR Products
5.2.4. MicroRNA
5.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
5.3.1. Academic Institutions
5.3.2. Pharmaceutical Companies
5.3.3. Biotechnology Companies
5.3.4. Contract Research Organizations
5.4. Market Analysis, Insights and Forecast, 2020-2035, By Scale
5.4.1. Custom Synthesis
5.4.2. Large Scale Production
5.4.3. Standardized Synthesis
5.5. Market Analysis, Insights and Forecast, 2020-2035, By Region
5.5.1. North America
5.5.2. Europe
5.5.3. Asia-Pacific
5.5.4. Latin America
5.5.5. Middle East and Africa
6. North America Oligonucleotide Synthesis Services Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
6.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
6.1.1. Research
6.1.2. Therapeutics
6.1.3. Diagnostic
6.1.4. Drug Discovery
6.2. Market Analysis, Insights and Forecast, 2020-2035, By Product Type
6.2.1. RNA Oligonucleotides
6.2.2. DNA Oligonucleotides
6.2.3. PCR Products
6.2.4. MicroRNA
6.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
6.3.1. Academic Institutions
6.3.2. Pharmaceutical Companies
6.3.3. Biotechnology Companies
6.3.4. Contract Research Organizations
6.4. Market Analysis, Insights and Forecast, 2020-2035, By Scale
6.4.1. Custom Synthesis
6.4.2. Large Scale Production
6.4.3. Standardized Synthesis
6.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
6.5.1. United States
6.5.2. Canada
7. Europe Oligonucleotide Synthesis Services Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
7.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
7.1.1. Research
7.1.2. Therapeutics
7.1.3. Diagnostic
7.1.4. Drug Discovery
7.2. Market Analysis, Insights and Forecast, 2020-2035, By Product Type
7.2.1. RNA Oligonucleotides
7.2.2. DNA Oligonucleotides
7.2.3. PCR Products
7.2.4. MicroRNA
7.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
7.3.1. Academic Institutions
7.3.2. Pharmaceutical Companies
7.3.3. Biotechnology Companies
7.3.4. Contract Research Organizations
7.4. Market Analysis, Insights and Forecast, 2020-2035, By Scale
7.4.1. Custom Synthesis
7.4.2. Large Scale Production
7.4.3. Standardized Synthesis
7.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
7.5.1. Germany
7.5.2. France
7.5.3. United Kingdom
7.5.4. Spain
7.5.5. Italy
7.5.6. Russia
7.5.7. Rest of Europe
8. Asia-Pacific Oligonucleotide Synthesis Services Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
8.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
8.1.1. Research
8.1.2. Therapeutics
8.1.3. Diagnostic
8.1.4. Drug Discovery
8.2. Market Analysis, Insights and Forecast, 2020-2035, By Product Type
8.2.1. RNA Oligonucleotides
8.2.2. DNA Oligonucleotides
8.2.3. PCR Products
8.2.4. MicroRNA
8.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
8.3.1. Academic Institutions
8.3.2. Pharmaceutical Companies
8.3.3. Biotechnology Companies
8.3.4. Contract Research Organizations
8.4. Market Analysis, Insights and Forecast, 2020-2035, By Scale
8.4.1. Custom Synthesis
8.4.2. Large Scale Production
8.4.3. Standardized Synthesis
8.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
8.5.1. China
8.5.2. India
8.5.3. Japan
8.5.4. South Korea
8.5.5. New Zealand
8.5.6. Singapore
8.5.7. Vietnam
8.5.8. Indonesia
8.5.9. Rest of Asia-Pacific
9. Latin America Oligonucleotide Synthesis Services Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
9.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
9.1.1. Research
9.1.2. Therapeutics
9.1.3. Diagnostic
9.1.4. Drug Discovery
9.2. Market Analysis, Insights and Forecast, 2020-2035, By Product Type
9.2.1. RNA Oligonucleotides
9.2.2. DNA Oligonucleotides
9.2.3. PCR Products
9.2.4. MicroRNA
9.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
9.3.1. Academic Institutions
9.3.2. Pharmaceutical Companies
9.3.3. Biotechnology Companies
9.3.4. Contract Research Organizations
9.4. Market Analysis, Insights and Forecast, 2020-2035, By Scale
9.4.1. Custom Synthesis
9.4.2. Large Scale Production
9.4.3. Standardized Synthesis
9.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America
10. Middle East and Africa Oligonucleotide Synthesis Services Market Analysis, Insights 2020 to 2025 and Forecast 2026-2035
10.1. Market Analysis, Insights and Forecast, 2020-2035, By Application
10.1.1. Research
10.1.2. Therapeutics
10.1.3. Diagnostic
10.1.4. Drug Discovery
10.2. Market Analysis, Insights and Forecast, 2020-2035, By Product Type
10.2.1. RNA Oligonucleotides
10.2.2. DNA Oligonucleotides
10.2.3. PCR Products
10.2.4. MicroRNA
10.3. Market Analysis, Insights and Forecast, 2020-2035, By End Use
10.3.1. Academic Institutions
10.3.2. Pharmaceutical Companies
10.3.3. Biotechnology Companies
10.3.4. Contract Research Organizations
10.4. Market Analysis, Insights and Forecast, 2020-2035, By Scale
10.4.1. Custom Synthesis
10.4.2. Large Scale Production
10.4.3. Standardized Synthesis
10.5. Market Analysis, Insights and Forecast, 2020-2035, By Country
10.5.1. South Africa
10.5.2. Saudi Arabia
10.5.3. UAE
10.5.4. Rest of Middle East and Africa
11. Competitive Analysis and Company Profiles
11.1. Market Share of Key Players
11.1.1. Global Company Market Share
11.1.2. Regional/Sub-Regional Company Market Share
11.2. Company Profiles
11.2.1. Marathon Pharmaceuticals
11.2.1.1. Business Overview
11.2.1.2. Products Offering
11.2.1.3. Financial Insights (Based on Availability)
11.2.1.4. Company Market Share Analysis
11.2.1.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.1.6. Strategy
11.2.1.7. SWOT Analysis
11.2.2. Bioneer
11.2.2.1. Business Overview
11.2.2.2. Products Offering
11.2.2.3. Financial Insights (Based on Availability)
11.2.2.4. Company Market Share Analysis
11.2.2.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.2.6. Strategy
11.2.2.7. SWOT Analysis
11.2.3. IDT
11.2.3.1. Business Overview
11.2.3.2. Products Offering
11.2.3.3. Financial Insights (Based on Availability)
11.2.3.4. Company Market Share Analysis
11.2.3.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.3.6. Strategy
11.2.3.7. SWOT Analysis
11.2.4. Thermo Fisher Scientific
11.2.4.1. Business Overview
11.2.4.2. Products Offering
11.2.4.3. Financial Insights (Based on Availability)
11.2.4.4. Company Market Share Analysis
11.2.4.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.4.6. Strategy
11.2.4.7. SWOT Analysis
11.2.5. BioRad Laboratories
11.2.5.1. Business Overview
11.2.5.2. Products Offering
11.2.5.3. Financial Insights (Based on Availability)
11.2.5.4. Company Market Share Analysis
11.2.5.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.5.6. Strategy
11.2.5.7. SWOT Analysis
11.2.6. Synthego
11.2.6.1. Business Overview
11.2.6.2. Products Offering
11.2.6.3. Financial Insights (Based on Availability)
11.2.6.4. Company Market Share Analysis
11.2.6.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.6.6. Strategy
11.2.6.7. SWOT Analysis
11.2.7. Eurofins Genomics
11.2.7.1. Business Overview
11.2.7.2. Products Offering
11.2.7.3. Financial Insights (Based on Availability)
11.2.7.4. Company Market Share Analysis
11.2.7.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.7.6. Strategy
11.2.7.7. SWOT Analysis
11.2.8. GenScript
11.2.8.1. Business Overview
11.2.8.2. Products Offering
11.2.8.3. Financial Insights (Based on Availability)
11.2.8.4. Company Market Share Analysis
11.2.8.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.8.6. Strategy
11.2.8.7. SWOT Analysis
11.2.9. Integrated DNA Technologies
11.2.9.1. Business Overview
11.2.9.2. Products Offering
11.2.9.3. Financial Insights (Based on Availability)
11.2.9.4. Company Market Share Analysis
11.2.9.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.9.6. Strategy
11.2.9.7. SWOT Analysis
11.2.10. LGC Group
11.2.10.1. Business Overview
11.2.10.2. Products Offering
11.2.10.3. Financial Insights (Based on Availability)
11.2.10.4. Company Market Share Analysis
11.2.10.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.10.6. Strategy
11.2.10.7. SWOT Analysis
11.2.11. SigmaAldrich
11.2.11.1. Business Overview
11.2.11.2. Products Offering
11.2.11.3. Financial Insights (Based on Availability)
11.2.11.4. Company Market Share Analysis
11.2.11.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.11.6. Strategy
11.2.11.7. SWOT Analysis
11.2.12. Pioneer Natural Resources
11.2.12.1. Business Overview
11.2.12.2. Products Offering
11.2.12.3. Financial Insights (Based on Availability)
11.2.12.4. Company Market Share Analysis
11.2.12.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.12.6. Strategy
11.2.12.7. SWOT Analysis
11.2.13. Azenta Life Sciences
11.2.13.1. Business Overview
11.2.13.2. Products Offering
11.2.13.3. Financial Insights (Based on Availability)
11.2.13.4. Company Market Share Analysis
11.2.13.5. Recent Developments (Product Launch, Mergers and Acquisition, etc.)
11.2.13.6. Strategy
11.2.13.7. SWOT Analysis

List of Figures

List of Tables

Table 1: Global Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 2: Global Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by Product Type, 2020-2035

Table 3: Global Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 4: Global Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by Scale, 2020-2035

Table 5: Global Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by Region, 2020-2035

Table 6: North America Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 7: North America Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by Product Type, 2020-2035

Table 8: North America Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 9: North America Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by Scale, 2020-2035

Table 10: North America Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by Country, 2020-2035

Table 11: Europe Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 12: Europe Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by Product Type, 2020-2035

Table 13: Europe Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 14: Europe Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by Scale, 2020-2035

Table 15: Europe Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 16: Asia Pacific Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 17: Asia Pacific Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by Product Type, 2020-2035

Table 18: Asia Pacific Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 19: Asia Pacific Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by Scale, 2020-2035

Table 20: Asia Pacific Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 21: Latin America Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 22: Latin America Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by Product Type, 2020-2035

Table 23: Latin America Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 24: Latin America Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by Scale, 2020-2035

Table 25: Latin America Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Table 26: Middle East & Africa Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by Application, 2020-2035

Table 27: Middle East & Africa Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by Product Type, 2020-2035

Table 28: Middle East & Africa Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by End Use, 2020-2035

Table 29: Middle East & Africa Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by Scale, 2020-2035

Table 30: Middle East & Africa Oligonucleotide Synthesis Services Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035

Frequently Asked Questions

Industry

Healthcare Market Research

Explore comprehensive market research reports covering all aspects of the Healthcare industry, including market size, growth trends, competitive landscape, and strategic insights.

View Industry Page
;